H.C. Wainwright & Co., LLC

We are pleased to have served as Co-Lead Manager for InflaRx’s $30 Million Follow-On offering. Learn more about H.C. Wainwright and see all of our transactions online at www.hcwco.com/transactions

Join Senior Healthcare Analyst Swayampakula Ramakanth (RK) for a virtual fireside chat with Evaxion Biotech A/S Chief Executive Officer, Christian Kanstrup, and Chief Scientific Officer, Birgitte Rønø, on Wednesday, February 19, at 10am EST. They’ll discuss the company’s 2025 milestones, pipeline strategy, and proprietary AI immunology platform. Evaxion Biotech is a clinical-stage techbio company leveraging AI to develop vaccines with enhanced efficacy for patients with unmet needs. Don’t miss out—register for HCW@Home here: https://lnkd.in/ex2Es64F

We are pleased to have served as Financial Advisor for Aligos Therapeutics’ $105 Million Follow-On offering. Learn more about H.C. Wainwright and see all of our transactions online at www.hcwco.com/transactions

We are pleased to have served as the Exclusive Placement Agent for Microbot Medical’s $13 Million Follow-On offering. Learn more about H.C. Wainwright and see all of our transactions online at www.hcwco.com/transactions

HCW’s Mitchell Kapoor and Raghuram Selvaraju will host a virtual KOL seminar tomorrow, featuring two payer representatives who play key roles in determining ELEVIDYS market access coverage. The discussion will address coverage limitations related to the June 2024 label update for DMD patients aged 4 and older, while contextualizing the EMBARK trial results and design to examine their impact on coverage decisions. Additionally, the session will cover the anticipated timelines for updating ELEVIDYS coverage policies in response to the expanded label.   Register here: https://lnkd.in/e2AghqKV

Candel Therapeutics President and Chief Executive Officer, Paul Peter Tak, will participate in a virtual fireside chat with covering HCW Research Analyst Vernon Bernardino on February 13 at 10am EST. Dr. Tak will be discussing the promising results of Candel’s Phase 3 study of CAN-2409 and share insights into the observed improvement in disease-free survival, as well as the potential for long-term advancements in cancer treatment. Register for the Candel Therapeutics HCW@Home at https://ct.to/Z7htbZb

Join Sam Tabar, Chief Executive Officer of Bit Digital | NASDAQ: BTBT, for an engaging conversation with HCW Research Analyst Kevin Dede on Wednesday, February 12, at 2:30 PM EST. Together, they will delve into the evolution of Bit Digital, a company that started with bitcoin mining and is now at the forefront of data center infrastructure. The discussion will cover the company’s expanding business model, including high-performance computing (HPC) services and hosting, while also highlighting its continued focus on bitcoin mining and the strategic conversion of Ethereum yield into additional bitcoin.   To register, visit https://ct.to/MpmvKiI

On Friday, February 7 at 3pm EST, join HCW’s Andres Maldonado and Andrew Fein for an in-depth virtual KOL call featuring Dr. Edwin A. Alvarez, Professor in the Department of Gynecologic Oncology and Gynecologic Oncology Clinical Trials Director at the University of California, San Francisco. Together, they will explore the rapidly evolving landscape of Gynecologic Oncology, focusing on the advancements in novel antibody-drug conjugate (ADC) therapies for cervical cancer, ovarian cancer, and other indications. The discussion will also cover key upcoming data releases at ASCO GU as well as throughout 2025, and conclude with a live Q&A. To join, register at https://ct.to/DZrMk4p

Join us this Thursday, February 6 at 11am EST for an exclusive KOL panel discussion, moderated by HCW Research Analyst Arthur He, featuring Dr. Kathryn Wagner, Professor Emerita of Neurology and Neuroscience at Johns Hopkins School of Medicine, and Dr. Nivedita Jerath, Neuromuscular Director at AdventHealth Neuroscience Institute. Together, they will explore the evolving landscape of care for Duchenne Muscular Dystrophy (DMD), focusing on the transformative potential of gene therapy and diving into the latest advancements, opportunities, and challenges in efforts to enhance the lives of DMD patients. Secure your spot at https://lnkd.in/gfFEFuEw

We are pleased to have served as the Exclusive Placement Agent for Elicio Therapeutics’ $10 Million Follow-On offering. Learn more about H.C. Wainwright and see all of our transactions online at www.hcwco.com/transactions